The Center for Disease Control and the Food and Drug Administration recommended a pause on distributing the Johnson and Johnson vaccine until further review, which is expected to take place on April 23.  

This is due to a series of rare blood clots seen in six female patients who received the vaccine. The women were ages 18-48 and the symptoms were seen within 6-13 days from the date of receiving the dose. 

The latest on this recommendation can be seen in this week’s episode of Newscene, the award-winning student-produced weekly newscast.

The clots occurred in less than one-in-one million doses administered, but the CDC and FDA made the recommendation for the pause out of caution, they said.

The American College of Obstetricians and Gynecologists also released a statement recommending pregnant women to choose the Moderna or Pfizer vaccine options as pregnancy already comes with risks of clotting. 

The Biden administration said it is confident the nation’s supply of Moderna and Pfizer vaccines will be enough to compensate for the pause in Johnson and Johnson supply.